Mousa Omar Y, Shah Rushikesh, Hajar Nasser, Landas Steve K
Department of Medicine, State University of New York-Upstate Medical University, 750 E Adams St, Syracuse, NY 13210, USA.
Department of Gastroenterology, State University of New York-Upstate Medical University, 750 E Adams St, Syracuse, NY 13210, USA.
World J Oncol. 2015 Jun;6(3):378-380. doi: 10.14740/wjon911w. Epub 2015 Jun 12.
The National Cancer Institute reports high incidence of renal cell carcinoma (RCC) in the US compared to other regions. However, pancreatic and periampullary metastasis are uncommon when only 17% of the RCC cases metastasize overall. We herein present a case series of four patients with periampullary or pancreatic metastatic disease following complete resection of RCC, evaluating their occurrences and outcomes. We reviewed the cases of four male patients retrospectively, mean age 75 years (range 65 - 87) who had a previous history of nephrectomy for RCC. They experienced recurrence with periampullary (two patients) or pancreatic (two patients) metastatic disease between 0 and 108 months (mean time 41.5 months) following primary tumor resection. In patients with periampullary metastasis, one had asymptomatic presentation with progressive dilatation of the pancreatic duct noted on surveillance CT scans. The other patient had iron deficiency anemia and melena with esophagogastroduodenoscopy (EGD) findings of large fungating infiltrative ulcerating mass in the area of the duodenal papilla (the only patient with metastasis to other sites: lungs and colon). As for those with pancreatic metastasis, one patient presented with hematuria and abdominal pain and was found to have pancreatic metastasis at the time of RCC diagnosis. The other patient was admitted for further workup of a mass in the pancreatic tail upon surveillance. Pathologic findings included high grade RCC in the metastatic foci. Management of such patients included: distal pancreatectomy in two patients without chemoradiation, one was awaiting Whipple procedure and received four cycles of sunitinib, while the last was a poor surgical candidate and received aminocaproic acid. Three patients are still alive to date. Optimal management is challenging given the very high risk of delayed relapse following tumor resection of the localized disease, leaving such cases with a very poor prognosis. Therefore to enhance survival, it is imperative to have careful stage-dependent surveillance in patients who have undergone a prior resection of RCC. We emphasize the importance of raising awareness for this unusual presentation. Disease recurrence as a pancreatic mass or hepatobiliary ductal dilatation might be more frequent than previously reported.
美国国立癌症研究所报告称,与其他地区相比,美国肾细胞癌(RCC)的发病率较高。然而,胰腺和壶腹周围转移并不常见,因为总体上只有17%的RCC病例会发生转移。我们在此报告一组4例RCC完全切除术后出现壶腹周围或胰腺转移疾病的病例系列,评估其发生情况和预后。我们回顾了4例男性患者的病例,他们的平均年龄为75岁(范围65 - 87岁),既往有因RCC行肾切除术的病史。他们在原发性肿瘤切除后的0至108个月(平均时间41.5个月)之间出现了壶腹周围转移(2例)或胰腺转移(2例)。在壶腹周围转移的患者中,1例无症状,在监测CT扫描中发现胰管逐渐扩张。另1例患者有缺铁性贫血和黑便,食管胃十二指肠镜检查(EGD)发现十二指肠乳头区域有巨大的蕈状浸润性溃疡性肿块(唯一有转移至其他部位:肺和结肠的患者)。至于胰腺转移的患者,1例患者表现为血尿和腹痛,在RCC诊断时发现有胰腺转移。另1例患者在监测时因胰腺尾部肿块入院进一步检查。病理结果显示转移灶为高级别RCC。此类患者的治疗包括:2例患者行远端胰腺切除术,未进行放化疗,1例患者等待Whipple手术并接受了4个周期的舒尼替尼治疗,而最后1例患者手术风险高,接受了氨基己酸治疗。3例患者至今仍存活。鉴于局限性疾病肿瘤切除后延迟复发的风险非常高,最佳治疗具有挑战性,此类病例的预后非常差。因此,为了提高生存率,对既往接受过RCC切除术的患者进行仔细的分期依赖性监测至关重要。我们强调提高对这种不寻常表现的认识的重要性。作为胰腺肿块或肝胆管扩张的疾病复发可能比以前报道的更频繁。